After completion of this module, you should be able to:
- Assess your compliance with evidence-based measures for the diagnosis and treatment of patients with Primary Immunodeficiency Disease.
- Select and implement appropriate interventions to improve compliance with the measures.
- Compare and contrast practice before and after the intervention(s) to identify possible improvements in the assessment of patients with Primary Immunodeficiency Disease.
- Morna Dorsey, MD MMSc FAAAAI
University of California San Francisco
- Ivan Chinn, MD
Baylor College of Medicine
- Lisa J. Kobrynski, MD MPH FAAAAI
- Elena Perez, MD PhD FAAAAI
University of Miami
- Panida Sriaroon, MD FAAAAI
University of South Florida
- Charlotte Cunningham-Rundles, MD, PhD
The Immunology Institute, Mt. Sinai Medical Center
- Samuel Gubernick, DO FAAAAI
Family Allergy, Asthma and Immunology Associates, Largo FL
Authors and Reviewers disclosed the following relevant financial relationships:
- Dr. Cunningham-Rundles: ADMA Biologics – clinical trial funding
- Dr. Kobrynski: Grifols – research funding
- Dr. Perez: Baxter – advisory board member; CSL Behring – advisory board member; Grifols - honorarium
All other authors and reviewers disclosed no relevant financial relationships.
The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Academy of Allergy, Asthma & Immunology designates this PI CME activity for a maximum of 20.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Allergy and Immunology MOC Statement
The American Board of Allergy and Immunology has approved this performance improvement module to meet the requirements for Part IV of their Maintenance of Certification (MOC) program.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).
This activity is available for credit May 1, 2019 through May 31, 2021.
This Performance Improvement Module and the associated clinical care measures are based on the Primary Immunodeficiency Disease (PIDD) quality measures developed by the AAAAI PIDD-Module Workgroup and the Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency developed jointly by the American Academy of Allergy, Asthma & Immunology (AAAAI) and the American College of Allergy, Asthma & Immunology (ACAAI). https://www.ncbi.nlm.nih.gov/pubmed/26371839